Neurology Academy’s Post

Our new #BrainHealthTimeMatters is now available: https://lnkd.in/eDavWAg So many have made this work possible. Our thanks go to Alexion Pharma Germany GmbH and Merck Healthcare for sponsoring the launch of this report and helping bring this work to all; to Roche, MS Society and Horizon, now part of Amgen for their critical support towards the development of the report; to the panel of authors Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, Giancarlo Comi, Kathy Costello, Michael Devlin, Jelena Drulovic, Emma Gray, Jodi Haartsen, Anne Helme, Jana Hlaváčová, Elisabeth Kasilingam, Yaou Liu, Thomas Mathew, Saul Reyes, Jérôme de Sèze and Mitzi Joi Williams M.D., FAAN and to the many members of the Working Groups named in the report who brought expertise and evidence to shape and support the recommendations. We thank you and look forward the next steps - collaborating with you and further stakeholders to support the implementation of the recommendations. #BrainHealthTM #BrainHealth #MSTimeMatters, #NMOSDTimeMatters, #MOGADTimeMatters, #MSBH #OHPF, The Sumaira Foundation, Sumaira Ahmed, EMSP - European Multiple Sclerosis Platform, MS International Federation (MSIF), Can Do MS

It’s published 👏 a collaboration with over 60 experts across geography and disciplines. Delve in and see what it can mean for you and how you can support the implementation of recommendations for #MS, #NMOSD, #MOGAD and related disorders. MS Brain Health Oxford Health Policy Forum #MSBH #BrainHealthTM #NMOSDTimeMatters #MOGADTimeMatters

📢 On the occasion of the #WorldAlzheimersMonth, we are proud to launch, in collaboration with EFPIA - European Federation of Pharmaceutical Industries and Associations, the Perspective Paper "Rethinking Alzheimer's Disease Pathway: From Diagnosis to Care." The aim of this report is not merely to document the status quo, but to challenge it—to rethink how we approach Alzheimer’s treatment, care and management. By offering a comprehensive review of current practices, identifying challenges, gaps and barriers, and proposing policy recommendations, this report seeks to reshape the Alzheimer’s disease healthcare pathway in ways that enhance outcomes and quality of life for all involved, and reduce the impact on society. 🔎 Read more here: https://lnkd.in/e_iSYZwN

We are excited to have our work presented at the upcoming AMCP Nexus Conference in Las Vegas this October. The results of our collaboration with Sun Pharma and key opinion leaders will be showcased in a poster titled "A Systematic Literature Review and Meta-Analysis of the Real-World Effectiveness, Quality of Life, and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis." This presentation highlights the practical benefits of tildrakizumab in real-world clinical settings, offering valuable insights into its efficacy and impact on patient quality of life. Our poster L17 will be displayed in The Expo – Marquee Ballroom on October 16 from 1:00 pm – 2:30 pm https://lnkd.in/g_VsFa7g

We would like to extend our sincere thanks to the sponsors who were instrumental in making the 2nd Congress on Rare Diseases for Latin America and the Caribbean possible. Your support enabled key discussions, including the need for clear public policies, the importance of international collaboration, and innovative models like Casa dos Raros in Brazil. Panels explored the role of regulatory agencies, health technology assessments, and innovative financing strategies for rare diseases. Advocacy leaders and patient testimonials reinforced the importance of continued stakeholder engagement and a unified approach to improving care for those living with rare diseases. With over 1,500 participants, the congress focused on advancing critical discussions around rare diseases and identifying practical solutions to improve diagnostics, access to treatment, and patient care in the region. A special thanks to our Platinum sponsors, Amgen and AstraZeneca, for their ongoing commitment to rare disease care. We also thank our Gold sponsors, Chiesi Group, Takeda, Johnson & Johnson, Valentech Pharma, and MSD, for their valuable contributions to advancing rare disease research. In addition, we appreciate the support of our Silver sponsors, Boehringer Ingelheim, Sanofi, ARCHIMEDlife Medical Laboratories, Illumina, JCR Pharmaceuticals, and Multicare Pharma, and our Allies, Optimal Therapies, Farmacon Global, and RARASCRO. We look forward to continuing our collaboration to drive progress in rare disease care across Latin America and the Caribbean. Learn more about AHF and our work: https://lnkd.in/drNVhhwU #RareDiseases #Collaboration #Innovation #PublicPolicy #Healthcare #AccessToCare #Congress #ThankYou #LatinAmerica

This is the message I would like policy makers and the society at large to hear: #Alzheimer is different now, we need to rethink the whole system around it. A great honour (and a pleasure) to have led the writing of this report in the context of the Rethinking Alzheimer's Disease project, coordinated by European Brain Council in collaboration with EFPIA - European Federation of Pharmaceutical Industries and Associations. I would like to thank all the members of this project for such a great collaboration. So, what is different now? - Alzheimer is not a mystery anymore -> thanks to scientific research we have started to understand the biological underpinnings of the clinical symptoms - it can be diagnosed early -> science has allowed us to identify markers for early and precise diagnosis, as well as targets for pharmacological treatment - it is treatable -> new treatments (potentially disease modifying) are starting to be approved, meaning that in the future Alzheimer will be treatable Like in oncology, we are moving towards #precisionmedicine, with early diagnosis as key for disease management (would you wait until stage 4 cancer to treat? I don't think so - so we should also not wait for the cognitive decline to be in its dementia stage before acting). Like in the field of multiple sclerosis at the time of the interferons, we are entering an era of new treatments (and look today how many treatment options exist for MS - it is not cured, but it's a disease that, with state of the art treatment, one can live with). This is all very exciting for a scientist like me, but how about patients? and caregivers? I have realized that without a profound societal and political change this new understanding will not reach the millions of patients and caregivers in need. The truth is, we are not ready for it. We do not have resources and facilities for early diagnosis, less so for treatment. But not doing it is not an option. Therefore, we need action. In this report we highlight current gaps and issues in post-diagnostic journey, and suggest structural and organizational changes to facilitate the implementation of this new vision of Alzheimer. Treating Alzheimer is important at several level - from the personal one (alleviating the burden of so many individuals and families, including millions of female caregivers), to the political one - preserving the brain health economy of the European population. We can't afford to do this wrong. Please help me spreading this paper and its message of hope and urgency for Alzheimer.

We need to call on policymakers to drive regional, national, EU, and international policies that can help to improve the lives of people living with the disease, define a post diagnostic pathway through sufficient guidelines and funds allocated for optimal implementation, which will also improve alignment and harmonisation of the pathways across the countries.

🚨 Update on Zeposia Phase 3 Trials for Crohn's Disease 🚨 Bristol Myers Squibb failed to meet primary endpoint of Phase 3 induction trials of the Phase 3 YELLOWSTONE clinical trial of #Zeposia for mod-to- sev CD 📊 Strategy: ⏩No S1P modulators have yet shown significant therapeutic benefits for CD ⏩Mitsubishi Tanabe Pharma's amiselimod, undergoing Phase 2 trials, didn't demonstrate significant improvement compared to placebo ⏩The approval of Velsipity and Zeposia for UC suggests that the potential for S1P modulators may be limited to UC 📅 What's Next? ⏩The company plans to unveil full results of the YELLOWSTONE trials in the future, although no specific timeline has been provided 🔜 Stay tuned for updates! Additionally, mark your calendars for the #DDW conference happening from May 18-21, 2024, where we anticipate further insights into the YELLOWSTONE program Bristol Myers Squibb #BMS #CrohnsDisease #Zeposia #ClinicalTrials #Healthcare Source: https://lnkd.in/gCSUf3HS

Join us in celebrating C. Ola Landgren, M.D., Ph.D., recipient of the Fierce 50 Breakthrough Honoree award for his groundbreaking work in advancing multiple myeloma treatment. Fierce 50 spotlights innovators and leaders driving the future of healthcare, pharma and biotech. Dr. Landgren’s journey began with an idea to improve diagnostic tools for detecting deeper remissions. Through over 15 years of rigorous research, collaboration and overcoming industry resistance, he proved the strong correlation between minimal residual disease (MRD) negativity and long-term progression-free survival (PFS). His efforts led to the FDA’s unanimous approval of MRD as a surrogate endpoint for accelerated drug approvals, a milestone that could reduce clinical trial timelines from a decade to just three years—enabling faster access to life-saving therapies for patients. This recognition honors Dr. Landgren’s unwavering commitment to improving patient outcomes. 🙌 Learn more: https://loom.ly/VcDfvvU. #OnlySylvester Fierce Pharma

Make use of our experts on patient recruitment and feasibility at the Nordic Life Science Days in Malmö next week!   On 18-19 September, Simon Klaasen and Ola Hasselgren will be there, ready to share their expertise in patient recruitment and feasibility studies. Whether you’re in the early stages of planning a clinical study or already writing your protocol, stop by our booth to explore how we can help boost your recruitment efforts.   Did you know? Our patient feasibility studies can provide crucial patient feedback before you even begin. By incorporating patient insights early, you can optimize your study and reduce the overall budget—saving time and resources while increasing your study’s success rate.   Don’t miss this opportunity to meet with us at NLSDays! Let’s discuss how we can make your next clinical trial more efficient and patient-focused.   Visit us at our stand or learn more at www.link2trials.com . Follow us!   #NLSDays #PatientRecruitment #ClinicalTrials #FeasibilityStudies #CRO #Pharma #MedTech #InvestInPatients #NordicStars #ClinicalExcellence #Link2Trials